Intercept’s NASH Drug Delayed By April Advisory Committee, But Firm Is Ready For Launch

 
• By Joseph Haas
  
liver
An FDA advisory committee for OCA was expected, but scheduling it after the PDUFA date was a surprise

More from New Products

More from Scrip